期刊文献+

三磷酸腺苷结合转运蛋白G超家族成员2基因在食管癌中的表达及意义 被引量:7

Expression of ATP-binding Cassette Transporter G2 Gene in Esophageal Carcinoma and its Significance
下载PDF
导出
摘要 目的探讨三磷酸腺苷结合转运蛋白G超家族成员2(ATP-binding cassette transporer G2,ABCG2)基因在食管癌组织中的表达及其意义。方法采用RT-PCR方法检测44例原发性食管癌患者的癌组织、癌旁组织(距离癌2cm)及食管切缘正常黏膜(距离癌5cm以上)ABCG2的mRNA表达。结果ABCG2在食管癌原发灶组织中有较高程度的表达,其表达量为0.77±0.11,而正常食管黏膜中的表达量为0.66±0.12;其在食管癌中的表达显著高于正常黏膜(P<0.01)。ABCG2在低分化鳞癌中的表达显著高于中-高分化鳞癌(P<0.05)。食管癌中ABCG2在年龄和性别间表达无显著性差异(P>0.05)。结论ABCG2在食管癌组织中高表达可能在某种程度上参与了食管癌原发性耐药及化疗中多药耐药的形成。其可作为一种新的引起多药耐药的分子,指导临床上食管癌的化疗。 Objective To explore the expression of ABCG2 in esophageal carcinoma and its significance. Methods The expressions of ABCG2 mRNA were detected by RT-PCR in 44 cases of esophageal carcinoma, paired adjacent mueosa to esophageal carcinoma and normal esophageal mucosa at surgical margin of esophageal carcinoma tissues. Results The expression of ABCG2 in esophageal carcinoma was higher significantly than that in normal esophageal mueosa (P 〈 0.01 ). The expression of ABCG2 in esophageal carcinoma was 0.77±0.11 and 0.66±0.12 in ormal mucosa. The expression of ABCG2 in poorly differentiated cancer was higher significantly than in moderately and well differentiated cancer (P 〈 0.05 ). The expression of ABCG2 in esophageal carcinoma was not related to age and gender (P 〉 0.05 ). Conclusion The high expression of ABCG2 may participate, to some extent,in the formation of esophageal muhidrug resistmlce, so it can be regarded as a new factor of multidrug resistance to guide the esophageal chemotherapy in clinic.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2008年第6期776-778,共3页 Journal of China Medical University
基金 河北省自然科学基金资助项目(C2007001060)
关键词 食管癌 三磷酸腺苷结合转运蛋白G超家族成员2 多药耐药 esophageal cancer ATP-binding cassette transporter G2 multidrug resistance
  • 相关文献

参考文献11

  • 1ZHOU S,SCHUETZ JD,BUNTING KD,et al. The ABC transporter Bcrpl /ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype [J].Nat Med, 2001,7(9) : 1028-1034.
  • 2DONNENBERG VS,DONNENBERG AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis [J]. J Clin Phamacol, 2005,45 (8) : 872-877.
  • 3PATRAWAKA L, CALHOUN T, SCHNEIDER-BROUSSARD R, et al. Side population is enriched in tumorigenic,stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic [J]. Cancer Res, 2005,65 (14) : 6207-6220.
  • 4HIRSHMANN-JAX C,FOSTER AE ,WULF GG,et al. A distinct " side population" of cells with high drug efflux capacity in human tumor cells[J] . PNAS,2004,101(39) : 14228-14233.
  • 5QINGCHENGi MAOo,JASHVANT D ,UNADKAT. Role of the cancer resistance protein (ABCG2) in drug transport [J] . The AAPS Journal, 2005,7( 1 ) : 118-134.
  • 6DOYLE LA,ROSS DD. Muhidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) [ J ] . Oncogene, 2003,22 (47) :7340-7358.
  • 7ALLIKMETS R,SCHRIML LM,HUTCHINSON A,et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance [J]. Cancer Res, 1998,58(23 ) : 5337-5339.
  • 8DOYLE LA,YANG W, ABRUZZO LV,et al. A muhidrug resistance transporter from human MCF-7 breast cancer cells [J]. Proc Natl Acad Sci USA, 1998,95(26) : 15665-15670.
  • 9BATRS SE, ROBEY R, MIYAKE K, et al. The role of half-transporters in multidrug resistance [J]. J Bioenerg Biomembr,2001,33 (6) : 503- 511.
  • 10KAWABATA S, OKA M, SODA H, et al. Expression and functional analyses of breast cancer resistance protein in lung cancer[J]. Clin Cancer Res,2003,9(8) :3052.

同被引文献84

  • 1孙瑞清,吴建农,陈淼.食管鳞癌组织中P-gp和nm23表达的意义及其对预后的影响[J].江苏大学学报(医学版),2006,16(5):406-408. 被引量:5
  • 2邹小农.食管癌流行病学[J].中华肿瘤防治杂志,2006,13(18). 被引量:63
  • 3张晓东.食管癌化学治疗现状[J].癌症进展,2007,5(1):13-17. 被引量:26
  • 4Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: rote of ATP-dependent transporters[J]. Nat Rev Cancer, 2002, 2 (1): 48-52.
  • 5Ceckova M, Libra A, Pavek P, et al. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo[J]. Clin Exp Pharmacol Physiol, 2006, 33(1-2): 58-63.
  • 6Nieolle E, Boccard J, Guilet D, et al. Breast cancer resistance protein (13CRP/ABCG2) :new inhibitors and QSAR studies by a 3D linear solvation energy approach[J]. Eur J Pharm Sci, 2009, 38(1): 39-45.
  • 7Mahringer A, Belzer J, Fricker G. A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2)[J]. Eur J Pharm Biopharm, 2009, 72(3):605-610.
  • 8Larbcharoensub N, Leopairat J, Sirachainan E, et al. A.ssociation between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent ehemotherapy[J]. Hum Pathol, 2008, 39(6) : 837-841.
  • 9Tsuruo T. Molecular cancer therapeutics: recent progress and targets in drug resistance[J]. Intern Med, 2003, 42(3):237-243.
  • 10Ozvegy C, Varadi A, Sarkadi B, Characterization of drug transport ATP hydrolysis, and nucleotide trapping by the human ABCG2 mul tidrug transporter. Modulation of substrate specificity by a point rnu tation[J]. J Biol Chem, 2002, 277(50): 47980-47984.

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部